Because reduction of α-synuclein can cause perturbations in striatal levels of dopamine, which could be an adverse side effect for treating PD [47–49], antibodies that specifically target fibrillar α-synuclein may be most effective in preventing the progression of PD without causing adverse side effects. Here, SNCA is linked to Parkinson disease.